As per reports, Boeing (BA) is offering CEO Dave Calhoun an incentive worth approximately $5.29 million to push him to stay throughout the company’s recovery from the crises of the COVID-19 pandemic and two deadly 737 MAX crashes that led to the fleet’s grounding incurring consecutive losses. On Feb 16, Boeing’s board approved giving 25,000 in restricted stock units to the CEO, with two installments on the first and second anniversary of the grant. The decision points out that Boeing’s current board of directors may not seek to replace Calhoun with a new CEO until at least the mid-2020s when the company is expected to return to pre-pandemic production rates.
In April 2021, Boeing extended its retirement age of 65 to 70 to allow Calhoun who turns 66 in April, to stay in the top job. The announcement of the award to Calhoun comes just weeks after the company reported its first yearly positive cash flow since 2018.
Dow 30 component Boeing (NYSE: BA) is the world’s largest aerospace company and leading manufacturer of commercial jetliners and defense, space, and security systems. To learn more about Boeing (BA) and to track its ongoing progress please visit the Vista Partners Boeing (BA) Coverage Page.
Stay Informed! Stay Competitive! Please join us at Vista Partners to receive our FREE email updates throughout the week and view our exclusive content and research. Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
DID YOU KNOW?…
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet need in cancer, today (Feb. 13, 2023) announced that the United States Patent and Trademark Office (USPTO) has granted a new patent (No. 11,572,334) directed to (Z)-endoxifen encapsulated in an enteric capsule. Enteric capsules have an acid resistant coating to prevent them from dissolving when they pass through the stomach. Enteric capsules are dissolved when they pass through an alkaline environment, which is usually when they reach the small intestine. Delivering oral (Z)-endoxifen via an enteric capsule prevents breakdown of the endoxifen in the stomach. A short ‘explainer’ video about the new patent can be found here: Patent Update – Video Explainer.
This patent further reinforces Atossa’s broad Intellectual Property portfolio related to (Z)-endoxifen. Atossa is developing its proprietary (Z)-endoxifen in both the breast cancer treatment and prevention settings. Phase 2 trials are ongoing with the goal of changing the treatment paradigm for patients who are not benefiting from currently approved drugs and helping reduce the incidence of breast cancer.
